Indications |
Oral Infections caused by susceptible pathogens Adult: 250-500 mg 4 times daily. Max 4 g daily. Child: >8 yr: 25-50 mg/kg daily in 4 divided doses. Renal impairment: Dosage may need to be reduced. Oral Acne Adult: 250-500 mg bid. Renal impairment: Dosage may need to be reduced. Oral Uncomplicated gonorrhoea Adult: 1.5 g initially, followed by 0.5 g four times daily up to a total of 9 g per treatment course. Renal impairment: Dosage may need to be reduced. Intramuscular Infections caused by susceptible pathogens Adult: 250 mg once daily or 300 mg daily in 2-3 divided doses. Child: >8 yr: 15-25 mg/kg (max 250 mg) daily in 2-3 divided doses. Renal impairment: Dosage may need to be reduced. Ophthalmic Superficial bacterial infections of the eye Adult: Used in combination with other agents: As ointment: Apply a small amount in the lower conjunctival sac of the infected eye 2-4 times daily. As suspension: Instill 1-2 drops into the affected eye tid. Topical/Cutaneous Infected dermatitis Adult: In combination with a topical steroid: Apply up to 4 times daily. |
Contraindications |
Hypersensitivity to tetracyclines, children <8 yr, renal damage. Pregnancy, lactation. |
Warnings / Precautions |
Elderly, renal or hepatic impairment; myasthenia gravis; lupus erythematosus, children <12 yr. |
Adverse Reactions |
Anorexia, nausea, vomiting,diarrhoea, glossitis, dysphagia, photosensitivity, oesphageal irritation and ulceration, nephrotoxicity, enterocolitis, rash (rare), blood dyscrasias. Headache, visual disturbances; intracranial hypertension; bulging fontanelles (infants). Potentially Fatal: Rare. Fulminant diarrhoea in post operative patients. |
Drug Interactions |
Antacids, iron, aluminum, calcium, magnesium, zinc salts reduce absorption. Concurrent use may cause increased levels of lithium, digoxin, halofantrine and theophylline; decreased concentrations of atovaquone. Increased risk of ergotism with ergot alkaloids. May cause failure of oral contraception. Potentially Fatal: Interferes with anticoagulant control. Nephrotoxic effects exacerbated by diuretics, methoxyflurane or other nephrotoxic drugs; avoid concurrent use with potentially hepatotoxic drugs. Increased incidence of benign intracranial hypertension with retinoids. See Below for More oxytetracycline Drug Interactions |
Lab Interactions |
Interferes with urinary glucose and catecholamine estimations. |
Food Interactions |
Absorption reduced by food, milk and milk products. Give 1 hr before or 2 hr after meals. |
Mechanism of Actions |
Oxytetracycline binds reversibly to the 30S and possibly 50S ribosomal subunits, thus inhibiting bacterial protein synthesis and arresting cell growth. It is active against a wide range of gram-positive and gram-negative organisms. Distribution: Protein-binding: 20-40% Metabolism: Hepatic (small amounts). Excretion: Urine, faeces; 9 hr (elimination half-life). |
Administration |
Should be taken on an empty stomach. (Take on an empty stomach 1 hr before or 2 hr after meals.) |
ATC Classification |
D06AA03 - Oxytetracycline ; Belongs to the class of topical tetracycline and derivatives agents used in the treatment of dermatological diseases. G01AA07 - Oxytetracycline ; Belongs to the class of antibiotics. Used in the treatment of gynecological infections. J01AA06 - Oxytetracycline ; Belongs to the class of tetracyclines. Used in the systemic treatment of infections. S01AA04 - Oxytetracycline ; Belongs to the class of antibiotics. Used in the treatment of eye infections. |
Available As |
|
Oxytetracycline
Post Review about Oxytetracycline Click here to cancel reply.
Oxytetracycline Containing Brands
Oxytetracycline is used in following diseases
Drug - Drug Interactions of Oxytetracycline
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.